<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03406273</url>
  </required_header>
  <id_info>
    <org_study_id>HITC001</org_study_id>
    <nct_id>NCT03406273</nct_id>
  </id_info>
  <brief_title>Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in Relapsed Neuroblastoma</brief_title>
  <official_title>A Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in Relapsed Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Giselle SaulnierSholler</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atrium Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HITC001 is a single institution study to evaluate the efficacy of using a standardized&#xD;
      protocol of surgery and radiation for patients with brain metastases in relapsed&#xD;
      neuroblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial aims to establish a standardized protocol consisting of surgery and&#xD;
      radiation for patients with brain metastases in relapsed neuroblastoma. This will be an&#xD;
      adjunct study to NMTRC009 onto which patients will be enrolled to for treatment with&#xD;
      precision therapy. This study will follow the efficacy, safety, and CNS progression-free&#xD;
      survival of surgery and radiation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No enrollment to study, study closed&#xD;
  </why_stopped>
  <start_date type="Anticipated">May 2017</start_date>
  <completion_date type="Actual">December 11, 2019</completion_date>
  <primary_completion_date type="Actual">May 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) of Participants by the presence of radiologically measurable CNS disease by cross-sectional CT or MRI imaging and/or by MIBG or PET scans and/or CSF Sampling.</measure>
    <time_frame>3 years</time_frame>
    <description>To determine the activity of treatments chosen based on Overall response rate (ORR) using RESIST criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety</measure>
    <time_frame>3 years</time_frame>
    <description>To determine the safety of using a standardized protocol of surgery and radiation for patients with brain metastases in relapse neuroblastoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) interval for CNS lesions will be measured by days from start of treatment (surgery/radiation) to the date of any future progressive disease (PD) in CNS lesions per RESIST criteria.</measure>
    <time_frame>3 years</time_frame>
    <description>Time to progression (PFS), defined as the period from the start of the treatment until the criteria for progression are met taking as reference the screening measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of time that participants experience Overall Survival (OS)</measure>
    <time_frame>8 years</time_frame>
    <description>Overall survival (OS) will be defined as the period in days from the date of enrollment until the date of death.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Relapsed Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>≥ 5 years of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cerebral Spinal (CS) radiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&lt; 5 yo and ≥ 3 yo and CSF +</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cerebral Spinal (CS) radiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>All &lt; 3 yo &amp; &lt; 5 yo/≥ 3 yo CSF neg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Focal radiotherapy (SRS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Cerebral Spinal (CS) radiation</intervention_name>
    <description>Surgery plus Cerebral Spinal (CS) radiation</description>
    <arm_group_label>&lt; 5 yo and ≥ 3 yo and CSF +</arm_group_label>
    <arm_group_label>≥ 5 years of age</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Focal radiotherapy (SRS)</intervention_name>
    <description>Surgery plus focal radiotherapy (stereotactic radiosurgery to the tumor bed [SRS])</description>
    <arm_group_label>All &lt; 3 yo &amp; &lt; 5 yo/≥ 3 yo CSF neg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: ≤ 21 years at the time of study entry.&#xD;
&#xD;
          -  Diagnosis: Histologic verification at either the time of original diagnosis or relapse&#xD;
             of neuroblastoma.&#xD;
&#xD;
          -  Disease Status: Patients must have ONE of the following along with disease in the CNS:&#xD;
&#xD;
               1. Any episode of recurrent disease following completion of aggressive multi-drug&#xD;
                  frontline therapy.&#xD;
&#xD;
               2. Any episode of progressive disease during aggressive multi-drug frontline&#xD;
                  therapy.&#xD;
&#xD;
               3. Primary resistant/refractory disease detected at the conclusion of at least 4&#xD;
                  cycles of aggressive multidrug induction chemotherapy on or according to a&#xD;
                  high-risk neuroblastoma protocols.&#xD;
&#xD;
          -  Measurable or evaluable disease by Brain MRI.&#xD;
&#xD;
          -  Current disease state must be one for which there is currently no known curative&#xD;
             therapy.&#xD;
&#xD;
          -  Meet all inclusion criteria for study NMTRC009&#xD;
&#xD;
          -  Informed Consent: All subjects and/or legal guardians must sign informed written&#xD;
             consent. Assent, when appropriate, will be obtained according to institutional&#xD;
             guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Meets all exclusion criteria for study NMTRC009&#xD;
&#xD;
          -  Subjects who, in the opinion of the investigator, may not be able to comply with the&#xD;
             safety monitoring requirements of the study, or in whom compliance is likely to be&#xD;
             suboptimal, should be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kaveh Asadi-Moghaddam, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Spectrum Health Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helen DeVos Children's Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 8, 2018</study_first_submitted>
  <study_first_submitted_qc>January 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Atrium Health</investigator_affiliation>
    <investigator_full_name>Giselle SaulnierSholler</investigator_full_name>
    <investigator_title>Beat Childhood Cancer Chair</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

